Cognito Therapeutics Raises $105M for Alzheimer’s Device | STAT News
Cognito Therapeutics, a Massachusetts-based medical device company, announced Thursday it has secured $105 million in Series C funding as it prepares for potential FDA clearance of its Alzheimer’s treatment device. The funding round was led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with participation from new investors, bringing the company’s total funding to $233 million. This latest investment follows a $35 million raise in early 2024 and a $50 million raise in 2022, signaling growing confidence in Cognito’s approach to addressing the debilitating neurodegenerative disease.
A New Approach to Alzheimer’s: Sensory Stimulation
Cognito is developing Spectris, a non-invasive device designed to combat cognitive decline associated with Alzheimer’s disease and other neurological conditions. The device, resembling a pair of sunglasses connected to headphones, delivers precisely calibrated gamma frequency light and sound stimulation for one hour daily, administered in the patient’s home. This approach is rooted in research originating from the Massachusetts Institute of Technology (MIT), suggesting that targeted sensory stimulation can aid restore disrupted brain activity. The underlying principle is to modulate brainwaves and potentially preserve brain structure, offering an alternative to pharmaceutical interventions.
How Gamma Stimulation Works
Gamma brainwaves, a type of neural oscillation, are associated with higher cognitive functions like memory and attention. In Alzheimer’s disease, these brainwaves are often diminished. Cognito’s Spectris device aims to boost these frequencies through external stimulation, theoretically strengthening neural connections and improving cognitive performance. Still, it’s crucial to understand that this is a relatively new area of research, and the precise mechanisms by which gamma stimulation impacts the brain are still being investigated. The company believes that by understanding how patients interact with the stimulation, they can build a large dataset to personalize treatment dosage over time.
Clinical Trials and the Path to FDA Clearance
Cognito is currently conducting a large-scale clinical trial to evaluate the efficacy and safety of Spectris. CEO Brent Vaughan anticipates completing the trial and submitting data to the Food and Drug Administration (FDA) for review by the end of 2025. The company is hoping for FDA clearance, which would allow them to market the device as a treatment for Alzheimer’s disease. The trial’s design and specific endpoints haven’t been publicly detailed, but the successful completion of this phase is critical for the company’s future. It’s key to note that FDA clearance doesn’t guarantee widespread adoption; factors like cost, insurance coverage, and physician acceptance will too play a role.
The Landscape of Alzheimer’s Treatment
The pursuit of effective Alzheimer’s treatments has been fraught with challenges. While recent approvals of drugs like lecanemab (Leqembi) and aducanumab (Aduhelm) offer a glimmer of hope, these medications come with limitations, including potential side effects and the need for regular infusions. Cognito’s device represents a different approach, offering a non-pharmacological option that could potentially complement or even offer an alternative to traditional drug therapies. The potential for at-home treatment is also a significant advantage, reducing the burden on patients and caregivers.
Data-Driven Personalization and the Future of Neurostimulation
A key aspect of Cognito’s strategy is its focus on data collection and analysis. The company aims to gather extensive data on patient responses to the gamma stimulation, with the goal of personalizing treatment protocols. CEO Vaughan envisions building a “world’s largest data set” to understand how to optimize dosage and tailor the stimulation to individual patient needs. This data-driven approach aligns with the broader trend towards personalized medicine, where treatments are customized based on an individual’s unique characteristics. This ambition is supported by the company’s growing Silicon Valley connections, suggesting a strong emphasis on technological innovation.
Understanding the Limitations
While the prospect of a non-invasive, at-home treatment for Alzheimer’s is encouraging, it’s essential to maintain a realistic perspective. The research on gamma stimulation is still evolving, and the long-term effects of this type of treatment are not yet fully understood. The clinical trial results will be crucial in determining whether Spectris is truly effective and safe. It’s important to remember that Alzheimer’s disease is a complex condition with multiple contributing factors, and a single treatment is unlikely to be a cure-all.
The company is led by CEO Brent Vaughan, and reporting on the company has been led by Mario Aguilar, a health tech correspondent at STAT, who also co-authors the STAT Health Tech newsletter. Aguilar’s coverage provides valuable insights into the evolving landscape of health technology.
What comes next: Cognito will focus on completing its clinical trial and analyzing the resulting data. The company plans to submit its findings to the FDA for review, with a target date of late 2025. The FDA’s decision will determine whether Spectris can be made available to patients with Alzheimer’s disease. Ongoing research will also be crucial to further refine the treatment protocol and explore its potential applications for other neurological conditions.